Dexcom (DXCM) EBITDA Margin (2010 - 2026)
Dexcom's (DXCM) quarterly EBITDA Margin came in at 21.42% in Q1 2026, up 851.0% year-on-year from 2.25% in Q1 2025, and down 16.47% on a QoQ basis from 25.64% in Q4 2025.
Dexcom (DXCM) EBITDA Margin (2010 - 2026) Analysis & Trends
Dexcom (DXCM) has 17 years of EBITDA Margin data on file, last reported at 21.42% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 851.0% year-over-year to 21.42% in Q1 2026; TTM through Mar 2026 was 21.45%, a 620.0% increase from a year earlier, with the FY2025 full-year figure at 19.56%, up 468.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 21.42%, down from 25.64% in the prior quarter.
- Over the last five years, EBITDA Margin for DXCM reached as high as 25.64% in Q4 2025 and fell as low as 6.37% in Q1 2023.
- Historically, EBITDA Margin has averaged 16.04% across 5 years, with a median of 15.73% in 2024.
- On a YoY basis, EBITDA Margin climbed as much as 1530 bps in 2022 and fell as far as 591 bps in 2022.
- Year by year, EBITDA Margin stood at 15.38% in 2022, then surged by 36 bps to 20.97% in 2023, then retreated by 19 bps to 16.96% in 2024, then surged by 51 bps to 25.64% in 2025, then fell by 16 bps to 21.42% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 21.42% in Q1 2026, 25.64% in Q4 2025, and 20.05% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Steris | 20.59 Bn | 20.16 Bn | 697.10 Mn | 19.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.42% |
| Dec 31, 2025 | 25.64% |
| Sep 30, 2025 | 20.05% |
| Jun 30, 2025 | 18.37% |
| Mar 31, 2025 | 12.91% |
| Dec 31, 2024 | 16.96% |
| Sep 30, 2024 | 15.29% |
| Jun 30, 2024 | 15.73% |
| Mar 31, 2024 | 10.98% |
| Dec 31, 2023 | 20.97% |
| Sep 30, 2023 | 21.08% |
| Jun 30, 2023 | 14.70% |
| Mar 31, 2023 | 6.37% |
| Dec 31, 2022 | 15.38% |
| Sep 30, 2022 | 19.17% |
| Jun 30, 2022 | 11.06% |
| Mar 31, 2022 | 6.57% |
| Dec 31, 2021 | 0.09% |
| Sep 30, 2021 | 18.19% |
| Jun 30, 2021 | 16.97% |